TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02888600

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Training
Description: Guided mindfulness meditation and stress management training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Guided health education and stress management training
Study: NCT00595023

Intervention type: DEVICE
Intervention: GeneSearch™ Breast Lymph Node (BLN) Assay
Description: The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
Study: NCT03882905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: 10 mg tablet, oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: 10 mg tablet, oral, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet, oral, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet, oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simivastatin
Description: Once daily administration at dose to be determined

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simivastatin
Description: Once daily administration at dose to be determined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Statin administered orally once daily at dose determined by treatment prior to enrollment by personal physician

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statin
Description: Statin administered orally once daily at dose determined by treatment prior to enrollment by personal physician
Study: NCT02797067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indomethacin suppository
Description: 100mg rectal indomethacin 30min before ESWL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glycerin Suppository
Description: 30min before ESWL
Study: NCT01893892

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: levocarnitine
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT02220309

Intervention type: DRUG
Intervention: Pramipexole Oral Tablet
Description: Pramipexole is an oral Dopamine agonist.
Study: NCT05323006

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scapular stabilization exercises
Description: the effect of the scapular stabilization exercise on the clavicular motion on the adolescent girls
Study: NCT02528565

Intervention type: DEVICE
Intervention: Adhesix Bioring
Study: NCT00928174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV administration of fluorine-18 fluorocholine followed by PET/CT imaging
Description: Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy.
Study: NCT04086433

Intervention type: DEVICE
Intervention: gastric tissue resection
Description: human stomach specimens will be resected with the surgical staplers for pressure testing and staple malformation assessment

Intervention type: DEVICE
Intervention: gastric tissue resection
Description: human stomach specimens will be resected with the surgical staplers for pressure testing and staple malformation assessment
Study: NCT03759860

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: R:GEN laser treatment (Selective Retina Therapy) and Lucentis (ranibizumab) combination therapy
Description: Lucentis (ranibizumab) injection into the vitreous cavity after R:GEN laser treatment (Selective Retina Therapy)

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: R:GEN laser treatment (Selective Retina Therapy) and Lucentis (ranibizumab) combination therapy
Description: Lucentis (ranibizumab) injection into the vitreous cavity after R:GEN laser treatment (Selective Retina Therapy)
Study: NCT02129153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIFT (Parent Information)
Description: 1. Parents will receive specific information about class assignments that the student missed or about poor performance on tests/quizzes. Parents will also be notified about behavioral problems, such as poor attention and class disruption. RA will communicate with parents in Spanish or English by text message, phone, email according to the parents preference for communication~2. Parents will be invited to parenting seminars to discuss parenting strategies regarding what to do with their child's academic and behavioral information once they receive it from research staff. Sessions will take place at school and last 2 hours. Multiple sessions will be offered throughout the academic year and parents may attend as many sessions as they wish.
Study: NCT03761446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bed rest
Description: The participant will remain in bed rest for 10 complete days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bed rest
Description: The participant will remain in bed rest for 10 complete days.
Study: NCT00852592

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 7000lux broad-spectrum light
Description: dosage - 15-60minutes NOON-2PM daily

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 50lux dim red light
Description: dosage: 15-60minutes NOON-2PM daily
Study: NCT04806698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menicon Z Night
Description: Children wearing Menicon Z Night orthokeratology contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Children wearing distance single-vision glasses or distance single-vision soft contact lenses
Study: NCT04757532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: 300 mg of bupropion hydrochloride (1 tablet) administered orally in a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg of anastrozole (1 tablet) administered orally in a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cyclopentylpropionate
Description: 100 mg of testosterone cyclopentylpropionate (equivalent to 70 mg of testosterone) administered via intramuscular injection in a single dose (2 mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Description: 200 mg of danazol (1 capsule) administered orally in a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Description: 50 mg of chlorthalidone (1 tablet) administered orally in a single dose.
Study: NCT04328051

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant Placement
Description: Antibiotic prophylaxis will be done. After rinsing with 0.12 % chlorhexidine, patients will receive local anaesthesia. A crestal incision will be done and a mucoperiostic flap will be raised. As the commercial specifies, progressive diameter drills will be used under constant sterile saline irrigation to prepare the implant site. Once finished the drilling sequence, one investigator will open the opaque envelope to know which type of implant, depending on the connection, has to be placed by the surgeon. Dental implant will be placed crestally and depending if it has primary stability or not, it will be leaded submerged or non-submerged. The flap will be repositioned and sutured without tension with 4/0 polyamide. Postoperative instructions and medication will be prescribed and explained.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant Placement
Description: Antibiotic prophylaxis will be done. After rinsing with 0.12 % chlorhexidine, patients will receive local anaesthesia. A crestal incision will be done and a mucoperiostic flap will be raised. As the commercial specifies, progressive diameter drills will be used under constant sterile saline irrigation to prepare the implant site. Once finished the drilling sequence, one investigator will open the opaque envelope to know which type of implant, depending on the connection, has to be placed by the surgeon. Dental implant will be placed crestally and depending if it has primary stability or not, it will be leaded submerged or non-submerged. The flap will be repositioned and sutured without tension with 4/0 polyamide. Postoperative instructions and medication will be prescribed and explained.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant Placement
Description: Antibiotic prophylaxis will be done. After rinsing with 0.12 % chlorhexidine, patients will receive local anaesthesia. A crestal incision will be done and a mucoperiostic flap will be raised. As the commercial specifies, progressive diameter drills will be used under constant sterile saline irrigation to prepare the implant site. Once finished the drilling sequence, one investigator will open the opaque envelope to know which type of implant, depending on the connection, has to be placed by the surgeon. Dental implant will be placed crestally and depending if it has primary stability or not, it will be leaded submerged or non-submerged. The flap will be repositioned and sutured without tension with 4/0 polyamide. Postoperative instructions and medication will be prescribed and explained.
Study: NCT00690833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical desonide hydrogel 0.05%
Description: apply the smallest amount of study medication possible that is just sufficient to cover all lesions of the standard cortisone-type medication twice daily (morning and evening) for up to 4 weeks to all of their AD lesions
Study: NCT01056133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omega-3 capsules-Fish Oil
Description: Patients will take 2 capsules (1.0 g each) of n-3 PUFA (0.82/0.44 g of EPA/DHA) daily x 12 months. Since n-3 PUFA supplementation can be a potential treatment for NASH and since BMI will be\< 30 kg/m2 for all subjects, patients will be told to keep their lifestyle, diet and medication stable (unless medically necessary) for the study duration in order to minimize environmental effect on gene expression.
Study: NCT03008447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEM5
Description: Single dose of lemborexant 5 mg administered within 5 minutes before bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEM5
Description: Single dose of lemborexant 5 mg administered within 5 minutes before bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEM5
Description: Single dose of lemborexant 5 mg administered within 5 minutes before bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEM5
Description: Single dose of lemborexant 5 mg administered within 5 minutes before bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEM10
Description: Single dose of lemborexant 10 mg administered within 5 minutes before bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEM10
Description: Single dose of lemborexant 10 mg administered within 5 minutes before bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEM10
Description: Single dose of lemborexant 10 mg administered within 5 minutes before bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEM10
Description: Single dose of lemborexant 10 mg administered within 5 minutes before bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZOL
Description: Single dose of zolpidem 6.25 mg administered within 5 minutes before bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZOL
Description: Single dose of zolpidem 6.25 mg administered within 5 minutes before bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZOL
Description: Single dose of zolpidem 6.25 mg administered within 5 minutes before bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZOL
Description: Single dose of zolpidem 6.25 mg administered within 5 minutes before bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBO
Description: Single dose of placebo administered within 5 minutes before bedtime.
Study: NCT03825809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Post-Operative Non Opioid Pain Protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone-Acetaminophen
Description: Traditionally used narcotic pain protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Post-Operative Non Opioid Pain Protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Post-Operative Non Opioid Pain Protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Post-Operative Non Opioid Pain Protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Post-Operative Non Opioid Pain Protocol
Study: NCT01202747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipiFlow System
Description: In-office treatment for meibomian gland dysfunction
Study: NCT02776709

Intervention type: PROCEDURE
Intervention: ERCP with cholangioscopy

Intervention type: PROCEDURE
Intervention: ERCP with cholangioscopy
Study: NCT01034319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Genetic Counseling
Description: Subjects will be genotyped based on a 37-allele aggregate score and counseled regarding the implications of the results prior to enrollment in a 12-week diabetes prevention program

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No genetic counseling
Description: These subjects will not be genotyped or counseled prior to enrollment in a 12-week diabetes prevention program
Study: NCT01456611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Diclofenac Sodium Gel 1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Diclofenac Sodium Gel 1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Topical Gel
Study: NCT00782509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744)
Description: Comparison of low and high doses on efficacy and safety in COPD patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744)
Description: Comparison of low and high doses on efficacy and safety in COPD patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler
Study: NCT03392974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Valoctocogene Roxaparvovec
Description: Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
Study: NCT02798484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted Nuclear Magnetic Resonance Imaging (MRI)
Description: MRI examinations performed on two devices: Ingernia 3 Testla (Philips) on the Horta site of the CHU Brugmann hospital, and Area 1,5 Tesla (Siemens) on the Brien site of the CHU Brugmann hospital. Diffusion sequences last 6 minutes and are already performed in the standard of care. Compared to the standard of care, one additional MRI will be performed one month after the start of the neo-adjuvant treatment, with diffusion analysis.The post-processing of the examinations will be realized with the Syngo Onco Care application of Siemens.
Study: NCT04359238

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individualized excercise
Description: The participants in the intervention group carry out regularly endurance and strength exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individualized excercise
Description: The participants in the intervention group carry out regularly endurance and strength exercises.
Study: NCT03665649

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CD133+ cells isolation
Description: Hematopoietic precursors from human donors will be mobilized by administering Colony Stimulating Factors (G-CSF) for 5 days (according to the clinical standard administration) and subsequently CD133+ cells will be isolated and transferred in a murine model.
Study: NCT03825900

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham OR active Transcranial direct current stimulation
Description: Sham OR active transcranial direct current stimulation over the motor cortex

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham OR active Transcranial direct current stimulation
Description: Sham OR active transcranial direct current stimulation over the motor cortex
Study: NCT00356200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluphenazine Decanoate
Description: Fluphenazine decanoate marketed by APP Pharmaceuticals (25 mg/mL, 5 mL vial) was used in this study. This was an ascending dose study with the first cohort of 5 subjects dosed at 10 µg/mL, followed by 5 subject dosed in the second cohort at 100 µg/mL. Note: APP Pharmaceuticals is the name of the pharmaceutical company; APP is not an acronym.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The sterile placebo (sesame oil with 1.2% (w/v) benzyl alcohol) was prepared at the University of Iowa, Division of Pharmaceutical Services, a FDA registered pharmaceutical manufacturing facility.
Study: NCT04238156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive abdominal exercises
Description: Three sessions per week during four consecutive weeks (Total: 12 sessions). Each session time: 30 minutes.
Study: NCT04502069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opaganib
Description: 500 mg Q12 hours orally
Study: NCT00628823

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten-free diet
Description: Gluten containing foods removed from diet
Study: NCT04764708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion and Metacognition Based Therapy
Description: The intervention is a Third Wave Cognitive Therapy targeting metacognitive dysfuctions (through Metacognitively Oriented Psychotherapy) and self-criticism (through Compassion Focused Therapy).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Standard Cognitive Behavioral Therapy for Personality Disorders plus Standard Psychopharmacological Treatment.
Study: NCT00577889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 750 mg/m2 Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 750 mg/m2 Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 750 mg/m2 Given IV
Study: NCT01224132

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: probiotic ® pur
Description: daily, four types of probiotic bacteria ( Bifidobacterium bifidity, Lactobacillus acidophilus, Lactobacillus casei and Lactobacillus salivarium) 2 bags (two billion bacteria) (probiotic ® pur) for a total of 8 (eight) weeks

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: probiotic ® pur
Description: daily, four types of probiotic bacteria ( Bifidobacterium bifidity, Lactobacillus acidophilus, Lactobacillus casei and Lactobacillus salivarium) 2 bags (two billion bacteria) (probiotic ® pur) for a total of 8 (eight) weeks
Study: NCT02873988

Intervention type: OTHER
Intervention: bronchial epithelial cell culture

Intervention type: OTHER
Intervention: bronchial epithelial cell culture
Study: NCT03472729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AGE-ON Workshop
Description: Series of workshops to reduce social isolation through technology use.
Study: NCT04699422

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane block
Description: The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance,30 cc Bupivacaine 0.25% will be injected in the deep compartment. After the deep component of the SAP is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. 10 cc Bupivacaine 0.25% will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: PCIA with Piritramide
Description: A patient controlled intravenous analgesia system (IVAC PCAM®, Cardinal Health or CADD pump) with piritramide (Dipidolor®, Janssen) using following settings: bolus 2 mg and lockout interval 15 min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCIA with Piritramide
Description: A patient controlled intravenous analgesia system (IVAC PCAM®, Cardinal Health or CADD pump) with piritramide (Dipidolor®, Janssen) using following settings: bolus 2 mg and lockout interval 15 min.
Study: NCT04456361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords
Description: Mesenchymal Stem Cells as a single-dose therapy via IV infusion at a dose of 1 X 10 8 cells.
Study: NCT01536223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF (cisplatin and 5-fluorouracil) group
Description: the group the patients using PF(cisplatin and 5-fluorouracil )neoadjuvant chemotherapy 3 cycles of neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 100mg/m2 and 5-fluorouracil 4000mg/m2 civ 120 hours And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPF (docetaxel plus cisplatin and 5-fluorouracil) group
Description: 3 cycles of TPF neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2,cisplatin75mg/m2 and 5-fluorouracil 2400mg/m2 civ 96 hours .~And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2.
Study: NCT04195165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIT
Description: For the SIT and SIT+EX conditions, the subject will be asked to take \<3,000 steps. This is meant to achieve \~12-13 hours of sitting per day, are the investigators are measuring the effect of inactivity and exercise on insulin sensitivity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIT
Description: For the SIT and SIT+EX conditions, the subject will be asked to take \<3,000 steps. This is meant to achieve \~12-13 hours of sitting per day, are the investigators are measuring the effect of inactivity and exercise on insulin sensitivity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTIVE
Description: For the ACTIVE+EX condition, the subject will be asked to take \>10,000 steps for the two intervention days. This is meant to simulate an active lifestyle.